Document is current
Any future updates will be listed below
-
Authors
Van Cauwenberge, Josephine
Van Baelen, Karen
Maetens, Marion
Geukens, Tatjana
Nguyen, Ha Linh
Nevelsteen, Ines
Smeets, Ann
Deblander, Anne
Neven, Patrick
Koolen, Stijn
Wildiers, Hans
Punie, Kevin
Desmedt, Christine https://orcid.org/0000-0002-5223-5579
-
Funding
Funding for this research was provided by:
the KU Leuven Fund Nadine de Beauffort
ASCO/Lobular Breast Cancer Alliance Young Investigator Award
European Research Council (FAT-BC 101003153, FAT-BC 101003153, FAT-BC 101003153)
- License Information
-
More Information
Article History
Received: 27 November 2023
Accepted: 30 April 2024
First Online: 22 May 2024
Declarations
:
: Not applicable.
: Not applicable.
: There are no conflicts of interest to declare for J.V.C., K.V.B., M.M., T.G., H.L.N., I.N., A.S., A.D., P.N., S.K. and C.D. KP: research grants paid to institution: MSD and Sanofi, speaker fees and honoraria for consultancy and advisory board functions: Astra Zeneca, Eli Lilly, Exact Sciences, Focus Patient, Gilead, MSD, Novartis, Pfizer, Roche, Seagen, speaker fees and honoraria for consultancy and advisory board functions paid to institution: Astra Zeneca, Eli Lilly, Exact Sciences, Gilead, MSD, Novartis, Pfizer, Roche, Seagen, stock options: Need Inc, travel grants: Astra Zeneca, Novartis, Pfizer, PharmaMar, Roche. HW: his institution received financial compensation on his behalf for advisory boards, lecture fees and/or consultancy fees from Immutep Pty, MSD, Astrazenca, Daiichi, AbbVie, Lilly, Roche, EISAI, Pfizer, Sirtex, Gilead. He received travel support from Pfizer and Roche.
